TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,008 | -85.7% | 13,200 | -75.4% | 0.00% | -100.0% |
| Q2 2023 | $823,296 | -89.6% | 53,600 | -84.8% | 0.00% | -88.9% |
| Q1 2023 | $7,934,180 | +39.1% | 352,787 | +30.1% | 0.03% | +28.6% |
| Q4 2022 | $5,703,588 | -58.1% | 271,212 | -51.0% | 0.02% | -22.2% |
| Q3 2022 | $13,625,886 | +22.2% | 552,994 | +20.2% | 0.03% | +28.6% |
| Q2 2022 | $11,150,081 | +19.1% | 460,180 | +26.7% | 0.02% | +61.5% |
| Q1 2022 | $9,361,682 | +1309.9% | 363,266 | +1597.5% | 0.01% | +550.0% |
| Q4 2021 | $664,000 | -84.2% | 21,400 | -92.6% | 0.00% | -66.7% |
| Q2 2021 | $4,200,000 | -48.0% | 287,800 | -11.1% | 0.01% | -76.0% |
| Q1 2021 | $8,083,000 | +55.9% | 323,718 | +70.2% | 0.02% | +56.2% |
| Q4 2020 | $5,184,000 | – | 190,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |